viewImmuPharma PLC

Immupharma PLC - Lupuzor Pivotal Phase III Study Update

RNS Number : 6822I
Immupharma PLC
23 March 2018

                                                                                                                                                                      23 March 2018


ImmuPharma PLC

("ImmuPharma" or the "Company")

Lupuzor™ Pivotal Phase III Study Update

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company announces  that it has been informed by Simbec-Orion, the contract research organisation conducting our Lupuzor™ pivotal Phase III trial study, that 'database lock' is expected on 6 April 2018, with top line results announced by mid-April 2018.

Lupuzor™ is the Company's lead programme for the potential breakthrough compound for Lupus, a life threatening autoimmune disease.

Commenting on the trial update, Tim McCarthy, Chairman, said: "With the continued robust safety record of Lupuzor™ achieved over this trial, we look forward with confidence to reporting top line results in the near future."

For more information on the trial please visit: https://clinicaltrials.gov/ct2/show/NCT02504645

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.


For further information please contact:


ImmuPharma plc (www.immupharma.com)

+ 44 (0) 20 7152 4080

Tim McCarthy, Chairman


Lisa Baderoon, Head of Investor Relations

Twitter: @immupharma


+ 44 (0) 7721 413496





Northland Capital Partners Limited

David Hignell, Dugald Carlean, Jamie Spotswood, Corporate Finance

Rob Rees, Corporate Broking




+44 (0)20 3861 6625





This information is provided by RNS
The company news service from the London Stock Exchange

Quick facts: ImmuPharma PLC


Price: 7.5

Market Cap: £18.77 m

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


ImmuPharma’s CEO, Tim McCarthy, presents commercial strategy for lupus drug...

ImmuPharma PLC (AIM:IMM)'s (LON:IMM) CEO, Tim McCarthy, presents commercial strategy for lupus drug Lupuzor™ as FDA approves PK study in advance to starting the Phase 3 trial, whilst also outlining the new Board’s plans on progressing the Company’s pipeline over the next 12 months.  The study...

on 17/8/21

2 min read